About this Research Topic
Breast cancer is the most common cancer in women. The HER2+ subtype is an aggressive type of breast cancer, which accounts for 15-25% of all breast cancers. The approval of multiple anti-HER2 targeted agents starting with trastuzumab in 1998 has significantly improved the prognosis of these patients.
The emergence of new anti-HER2 targeted therapies, such as pertuzumab, lapatinib, pyrotinib, neratinib, tucatinib, trastuzumab emtansine, trastuzumab deruxtecan and trastuzumab duocarmycin, has brought great progress in the treatment of HER2+ breast cancer. However, early recurrence and progression of disease while on targeted therapy still occur. In this Research Topic, we aim to create a forum for discussion of recent advances in the treatments of HER2+ breast cancer, including the discovery of new targets or agents, novel methods in pre-clinical or clinical trials, as well as deeper insights focusing on the known agents. We welcome Original Research, Clinical Trials, and Review articles focusing on but not limited to the following aspects:
• Clinical trials on new agents or regimens for HER2+ breast cancer
• Mechanisms of recurrence and resistance to anti-HER2 therapy and identification of druggable targets
• Translational research of HER2+ breast cancer, including but not limited to biomarkers or models
• Early diagnosis and treatment of central nervous system metastasis of HER2+ breast cancer
• Diagnostic strategies to better characterize (1) residual disease after neoadjuvant therapy and (2) disease progressing on targeted therapy
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.